Rapid and deep clinical responses to HLX79 (E-602), a first-in-class human sialidase-Fc fusion protein, plus HLX01, a rituximab biosimilar, in patients with membranous nephropathy: a Ph2 trial

Hanlikang (rituximab biosimilar) - Eurofarma, Farma de Colombia, Abbott, Shanghai Henlius Biotech

Zhilian Li, MD

Sep 8, 2026